Last10K.com

Affymax Inc (AFFY) SEC Filing 10-Q Quarterly report for the period ending Monday, June 30, 2014

Affymax Inc

HISTORY TOOLS
CIK: 1158223 Ticker: AFFY




Affymax and Takeda Announce Termination of Omontys® (peginesatide)
Product Collaboration and License Agreement

Takeda will withdraw the Omontys U.S. New Drug Application (NDA)

Cupertino, CA (June 13, 2014) and Osaka, Japan, (June 16, 2014)
– Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) announced today that their Omontys® (peginesatide) product collaboration and license agreement will terminate effective September 10, 2014.

In February 2013, Affymax and Takeda voluntarily recalled all lots of Omontys and suspended promotional activities in the U.S. following postmarketing reports of serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal.

Takeda has conducted a detailed investigation of these reactions. The investigation has confirmed no quality or manufacturing issues were present but has not identified a specific root cause for the reactions that were observed.

Based on these findings and related discussions with Takeda, Affymax has elected not to exercise its rights with respect to the Omontys New Drug Application (NDA). Takeda will work with the U.S. Food and Drug Administration to withdraw the Omontys NDA.

The Board of Directors of Affymax is reviewing its strategic options as a result of the termination of the collaboration with Takeda.

This termination does not change the outlook for Takeda's consolidated results for fiscal 2014.

About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company based in Cupertino, California. For additional information, please visit www.affymax.com.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through


The following information was filed by Affymax Inc (AFFY) on Friday, June 13, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Affymax Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Affymax Inc.

Continue

Assess how Affymax Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Affymax Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: AFFY
CIK: 1158223
Form Type: 10-Q Quarterly Report
Accession Number: 0001158223-14-000013
Submitted to the SEC: Thu Jul 31 2014 4:11:14 PM EST
Accepted by the SEC: Thu Jul 31 2014
Period: Monday, June 30, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/affy/0001158223-14-000013.htm